Skin & cosmetic
Palmitoyl Tetrapeptide-7
Pal-GQPR, Matrixyl component
Palmitoyl Tetrapeptide-7 is a lipidated tetrapeptide used in anti-ageing skincare, most often combined with Palmitoyl Tripeptide-1. Its proposed role is anti-inflammatory rather than directly collagen-stimulating.
Also known as: Pal-GQPR, Matrixyl 3000, palmitoyl tetrapeptide
- Status
- Palmitoyl Tetrapeptide-7 is used as a cosmetic or over-the-counter ingredient, not as an approved drug.
- Evidence
- Early human data. Only small or early-phase studies in people so far.
- Half-life
- Not applicable — acts locally in skin.
- How it's taken
- Topical, in a leave-on serum or cream
- Mechanism
- Cosmetic / topical
- Pathways
- Collagen Synthesis
How Palmitoyl Tetrapeptide-7 works
The GQPR sequence is derived from immunoglobulin G. In cell culture it reduces production of interleukin-6 and other inflammatory mediators. The rationale is that chronic low-grade inflammation — "inflammaging" — drives matrix degradation, so suppressing it complements a peptide that stimulates matrix synthesis. Palmitoylation improves skin penetration.
What research has looked at
- It targets a genuinely distinct mechanism from the collagen-signalling peptides, which is the rationale for the standard pairing.
- Reduced interleukin-6 production in fibroblast culture is a reproducible in vitro finding.
- Well tolerated, without the irritation associated with actives such as retinoids or acids.
Evidence level: Early human data. Only small or early-phase studies in people so far. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Cosmetic peptide claims are supported largely by manufacturer-funded studies with small numbers and short duration; independent replication is uncommon.
- Skin penetration is the central unresolved question for topical peptides — most are too large and too hydrophilic to cross the stratum corneum efficiently, and formulation determines far more than the peptide itself.
- The link between reduced in vitro interleukin-6 and visible skin improvement in people is inferred rather than demonstrated.
- Effects are modest and require months of consistent use.
- It is a cosmetic ingredient, not a drug, and is not evaluated by the FDA for efficacy.
Sources
- PubMed research on palmitoyl tetrapeptide-7 interleukin-6 skin · NIH · National Library of Medicine
- DrugBank record for palmitoyl tetrapeptide-7 · DrugBank
- Active clinical trials for palmitoyl tetrapeptide-7 · U.S. National Library of Medicine
Track Palmitoyl Tetrapeptide-7 in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Palmitoyl Tetrapeptide-7 FAQ
What is Palmitoyl Tetrapeptide-7?
Palmitoyl Tetrapeptide-7 is a lipidated tetrapeptide used in anti-ageing skincare, most often combined with Palmitoyl Tripeptide-1. Its proposed role is anti-inflammatory rather than directly collagen-stimulating.
How does Palmitoyl Tetrapeptide-7 work?
The GQPR sequence is derived from immunoglobulin G. In cell culture it reduces production of interleukin-6 and other inflammatory mediators. The rationale is that chronic low-grade inflammation — "inflammaging" — drives matrix degradation, so suppressing it complements a peptide that stimulates matrix synthesis. Palmitoylation improves skin penetration.
Is Palmitoyl Tetrapeptide-7 FDA approved?
No. Palmitoyl Tetrapeptide-7 is used as a cosmetic or over-the-counter ingredient, not as an approved drug. Evidence level: early human data. Only small or early-phase studies in people so far.
What is the half-life of Palmitoyl Tetrapeptide-7?
Reported half-life: Not applicable — acts locally in skin.
How is Palmitoyl Tetrapeptide-7 taken?
Topical, in a leave-on serum or cream.
What side effects have been reported with Palmitoyl Tetrapeptide-7?
Reported in the sources: Cosmetic peptide claims are supported largely by manufacturer-funded studies with small numbers and short duration; independent replication is uncommon; Skin penetration is the central unresolved question for topical peptides — most are too large and too hydrophilic to cross the stratum corneum efficiently, and formulation determines far more than the peptide itself; The link between reduced in vitro interleukin-6 and visible skin improvement in people is inferred rather than demonstrated; Effects are modest and require months of consistent use; It is a cosmetic ingredient, not a drug, and is not evaluated by the FDA for efficacy.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.